The latest Investing Matters Podcast episode with London Stock Exchange Group's Chris Mayo has just been released. Listen here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,516.00
Bid: 12,304.00
Ask: 12,600.00
Change: 0.00 (0.00%)
Spread: 296.00 (2.406%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 12,516.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Global stocks rise ahead of Fed meeting

Tue, 16th Mar 2021 19:47

* Graphic: Global asset performance http://tmsnrt.rs/2yaDPgn

* Graphic: World FX rates http://tmsnrt.rs/2egbfVh

By Herbert Lash

NEW YORK, March 16 (Reuters) - Wall Street's S&P 500 index
scaled a new high on Tuesday and a gauge of global equities
neared an all-time peak as investors bet the Federal Reserve and
other central banks meeting this week will retain policies
supporting a post-pandemic recovery.

U.S. stocks retreated late in the session, with the Nasdaq
shedding more than a 1% gain, as yields on longer-maturity U.S.
Treasury bonds ticked up, nipping investor enthusiasm for
tech-stocks that are high growth but wary of rising inflation.

The U.S. dollar edged up against the euro and commodity
currencies such as the Australian and New Zealand dollars as the
two-day Fed meeting kept trading from being volatile.
.

But oil prices fell for a third day after Germany, France
and other European countries suspended use of AstraZeneca's
vaccine, threatening economic growth and fuel demand, and
tarnishing roll-outs as a pillar for a global recovery.

Speculation about what the Fed will say on Wednesday at the
end of its two-day meeting kept markets mostly range-bound.

"The hope out there, for at least some investors, is they do
an Operation Twist - buying long-term bonds and selling short
bonds to help the economy," said Tim Ghriskey, chief investment
strategist at Inverness Counsel in New York.

The Nasdaq rose to a two-week high on a rebound in tech
stocks at the heart of February's sell-off. MSCI's benchmark for
global equity markets, which is heavily weighted to the big U.S.
technology firms, advanced 0.3% to 679.01.

After the coronavirus pandemic, demand will increase further
for technology stocks, according to Johan Grahn, head of ETF
strategy at AllianzIM in Minneapolis.

"As long as technology is solving real problems for people,
there will continue to be a market for these types of
companies," Grahn said. "There will be more demand for
technology solutions across the board."

European stocks rose after an upbeat forecast from German
carmaker Volkswagen prompted a rally in the automobiles sector.
The broad FTSEurofirst 300 index rose 0.8%, closing in
on its record peak of February 2020, while the regional autos
sector jumped 2.1% to its highest level since June 2018.

On Wall Street, the Dow Jones Industrial Average fell
0.19%, the S&P 500 gained 0.07% and the Nasdaq Composite
added 0.36%.

Euro zone government bonds held ground as caution set in
before the Fed meeting.

Longer-term U.S. Treasury yields initially slipped as the
market looked ahead.

The 10-year U.S. Treasury note rose 0.4 basis
points to yield 1.6109%. Yields on the benchmark last week hit
1.642% on expectations of rising inflation.

The Fed is targeting maximum employment and higher inflation
expectations, and will do whatever it can to get higher
inflation, said Steven Ricchiuto, U.S. chief economist at Mizuho
Securities USA LLC in New York.

"This is what is motivating the sell-off in the 10-year
note, and there are a lot of people who are just basically
coming around to recognizing that," Ricchiuto said.

Fed policymakers are expected to forecast the U.S. economy
will grow in 2021 by the fastest rate in decades as it recovers
from a coronavirus-stricken 2020.

The Bank of England also meets this week, on Thursday, and
the Bank of Japan wraps up a two-day meeting on Friday.

The outlook for post-pandemic recoveries continued to
diverge between the United States and Europe.

President Joe Biden's order to make vaccinations available
to all adults by May 1 contrasted with stuttering roll-outs in
Germany, France and elsewhere, where use of the AstraZeneca
vaccine has been suspended amid concern over possible
serious side-effects.

In currencies, the dollar held small gains from overnight,
with caution evident ahead of the central bank meetings.

The dollar index rose 0.001%, with the euro
down 0.17% to $1.1908.

The Japanese yen strengthened 0.14% versus the
greenback at 108.97 per dollar.

Gold edged lower, pressured by a stronger dollar. U.S. gold
futures settled up 0.1% at $1,730.90.

Europe's medicines watchdog said the benefits of the
AstraZeneca vaccine outweigh its risks, but investors worry the
slow pace of vaccinations in the European Union could dampen
both the recovery and fuel demand.

Brent crude futures settled down 49 cents at $68.39
a barrel and U.S. crude futures fell 59 cents to settle
at $64.80 a barrel.

(Reporting by Herbert Lash with additional reporting by Ritvik
Carvalho in London and by Kevin Buckland and Kane Wu in Tokyo
Editing by Mark Potter and Mark Heinrich)

More News
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more
30 May 2024 09:23

LONDON BROKER RATINGS: Jefferies and UBS cut Anglo American

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning and on Wednesday:

Read more
30 May 2024 07:40

LONDON BRIEFING: Dr Martens cuts payout as profit plummets

(Alliance News) - Stocks in London are called to open lower on Thursday, with investors nervous ahead of Friday's US inflation print.

Read more
29 May 2024 08:54

IN BRIEF: AstraZeneca drug lowers cholesterol in phase 1 trial

AstraZeneca PLC - Cambridge, England-based pharmaceuticals - Reports positive results in a phase 1 trial of cholesterol drug candidate AZD0780, an oral small molecule PCSK9 inhibitor. Administered on top of rosuvastatin treatment, AZD0780 showed a statistically significant reduction in low-density lipoprotein cholesterol in plasma for test participants with hypercholesterolaemia, Astra says, while no serious adverse events were reported. "Elevated LDL-C levels in plasma is a key risk factor for cardiovascular disease and is estimated to cause 2.6 million deaths worldwide annually," Astra notes.

Read more
28 May 2024 07:02

AstraZeneca experimental lung cancer drug shows promising results

(Sharecast News) - AstraZeneca's experimental lung cancer drug showed improved overall survival rates in phase III trials, the pharmaceutical giant said on Tuesday.

Read more
27 May 2024 07:49

IN BRIEF: Astra, Daiichi hail positive survival data for Dato-DXd

AstraZeneca PLC - Cambridge, UK-based pharmaceutical firm - Alongside Japan's Daiichi Sankyo Co Ltd, notes positive data for datopotamab deruxtecan in phase III trial on lung cancer. Says the treatment, also known as Dato-DXd, showed a clinically meaningfully improvement in overall survival versus chemotherapy in advanced nonsquamous non-small cell lung cancer. The results build upon the positive progression-free survival findings presented back in 2023, Astra adds.

Read more
22 May 2024 09:53

LONDON BROKER RATINGS: Barclays cuts NextEnergy but lifts JLEN

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
22 May 2024 02:00

British firms expecting hard time in China market, lobby group warns

BEIJING, May 22 (Reuters) - British firms expect doing business in China to become harder over the next five years, a British business lobby group said on Wednesday, as Beijing strives to halt a retreat in foreign funds from a market once seen as the engine of global growth.

Read more
21 May 2024 19:00

Sector movers: Stocks slip amid light profit-taking

(Sharecast News) - Stocks ended a tad lower as investors waited on a raft of US central bank speakers scheduled for after the close of markets in London.

Read more
21 May 2024 17:20

Europe's STOXX 600 ends lower as rate uncertainty prevails

Focus on Fed minutes, Nvidia earnings

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.